Collectively, this work provides new insight for understanding microbiome‐related immunotherapy resistance and offers innovative tactics to subdue the resistance of anti‐tumor immune therapy, which may benefit cancer patients who do not respond to anti‐PD‐1/PD‐L1 therapy. Here, CD274 is linked to cancer.